Patent Law Weblog
recent posts
- Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (2026)
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
about
Month: November 2009
-
By Donald Zuhn — Last week, Defendant-Appellant Eli Lilly & Co. filed its principal brief for the rehearing en banc of Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., which is scheduled for December 7th. (Patent Docs provided a summary of Ariad's principal brief, which was filed on October 5th, last Tuesday; see "Next…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Monsanto Co. et al. v. Germann4:09-cv-01848; filed November 11, 2009 in the Eastern District of Missouri • Plaintiffs: Monsanto Co.; Monsanto Technology LLC•…
-
November 16-17, 2009 – Patent Litigation 2009 (Practising Law Institute) – New York, NY November 17-18, 2009 – Structuring, Negotiating, and Managing Pharma/Biotech Collaborative Agreements (American Conference Institute) – New York, NY November 19, 2009 – Patentable Subject Matter After the Bilski Oral Argument (American University Washington College of Law and the Federal Circuit Bar…
-
On Thursday, November 19, 2009, the American University Washington College of Law Program on Information Justice and Intellectual Property and the Federal Circuit Bar Association (FCBA) will be offering a panel discussion entitled "Patentable Subject Matter After the Bilski Oral Argument." The panel discussion, which will be held in Room 603 at the Washington College…
-
By Kevin E. Noonan — Chief Judge Paul Michel, writing for most of the en banc Court of Appeals for the Federal Circuit (Judge Lourie took no part in the decision), today granted the joint motion of all parties to dismiss the appeal of Tafas v. Kappos. Thus, the infamous "continuation and claims rules"…
-
By Christopher P. Singer — PAIR Maintenance The USPTO posted a message on the front page of PAIR announcing that both Public and Private PAIR will be down for maintenance for part of this weekend. The maintenance is expected to begin at 10:00 pm EST on Saturday, November 14th and last until about 11:00…
-
By Donald Zuhn — On Tuesday, the U.S. Patent and Trademark Office announced that USPTO Director David Kappos (at right) has launched a new blog "to foster a direct dialogue with the USPTO's stakeholders and the general public." The blog, running under the heading "Director's Forum: David Kappos' Public Blog," can be reached through…
-
By Christopher P. Singer — On October 27, 2009, the U.S. Patent and Trademark Office published a notice in the Federal Register (74 Fed. Reg. 55212) outlining a new "Patents Ombudsman Pilot Program." The program is intended to provide patent applicants and practitioners with an additional resource for application-specific prosecution issues, particularly when prosecution…
-
By Suresh Pillai — Infosint Seeks Increased Damages Award in Citalopram Suit Following a decision by the U.S. District Court for the Southern District of New York in October finding Forest Laboratories and Lundbeck A/S liable for infringement of Infosint's patent covering the antidepressant citalopram, Infosint has now returned to the District Court seeking…
-
By Donald Zuhn — With oral argument before the Supreme Court in In re Bilski now concluded, patent practitioners can begin to turn their attention toward the next big patent case awaiting oral argument: the Federal Circuit's en banc rehearing of Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., which is scheduled for December 7th. …
Patent Docs 